Literature DB >> 28695784

Provision of powered communication aids in the United Kingdom.

Simon Judge1,2, Pam Enderby1, Sarah Creer1, Alex John1.   

Abstract

AAC service provision in the United Kingdom (UK) has evolved since the first service dedicated to the provision of communication aids opened in 1986. Within the UK, many health and care services are provided via government funding; however, the assessment and provision of AAC and specifically of speech-generating devices (SGDs) is inconsistent and inequitable. The study reported in this paper aimed to collect information on levels of current provision of powered communication aids (the term used in the study to refer to SGDs) by UK service providers in 2013 with the intention of improving future estimates for need of services. A questionnaire survey was designed and data were obtained from 98 AAC services across the UK. Service providers reported the number of individuals known to be using powered communication aids and the mean value reported was 0.0155% of the services' catchment populations. However levels of service provision reported were highly variable. Although the data reported must be treated with caution, it adds to the sparse literature on the topic, informs AAC service design and delivery in the UK, and acts as an indicative baseline measure for future service development.

Entities:  

Keywords:  AAC service delivery; United Kingdom; caseload; incidence; powered communication aids; prevalence; speech-generating devices

Mesh:

Year:  2017        PMID: 28695784     DOI: 10.1080/07434618.2017.1347960

Source DB:  PubMed          Journal:  Augment Altern Commun        ISSN: 0743-4618            Impact factor:   2.214


  1 in total

1.  Finding the best fit: examining the decision-making of augmentative and alternative communication professionals in the UK using a discrete choice experiment.

Authors:  Edward J D Webb; Yvonne Lynch; David Meads; Simon Judge; Nicola Randall; Juliet Goldbart; Stuart Meredith; Liz Moulam; Stephane Hess; Janice Murray
Journal:  BMJ Open       Date:  2019-12-01       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.